Recordati SpA (Recordati) develops, manufactures, and commercializes drugs for primary care and orphan drugs for the treatment of rare diseases. It provides an array of pharmaceuticals, both proprietary and under license, for various disease conditions including a specialized segment committed to treating rare diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D activities focus primarily on developing treatments for rare diseases. Recordati is intensifying its commitment to the advancement of rare disease research and development, with a portfolio of ongoing projects at various stages of advancement, encompassing formulation discovery, late-stage studies, and post-approval investigations. The company’s pipeline includes Cystadrops for Corneal cysteine crystal deposits in patients with cystinosis; Reagila for schizophrenia; Carbaglu for hyperammonemia due to deficiency of N-Acetyl Glutamate Synthase (NAGS) and to the main organic acidemias; REC 0559 which completed Phase 2 for neurotrophic keratitis; Istrusia for endogenous cushing’s syndrome/ cushing’s disease; Qarziba for the treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction; Sylvan for the treatment of idiopathic multicentric castleman disease (iMCD); Eligard for hormone-dependent prostate cancer and REC 0545 for acute decompensation episodes in maple syrup urine disease (MSUD). Its R&D center includes Parma (Italy), Paris (France), Cary (the US), Lidingo (Sweden), Chippenham (the UK), Shanghai (China) and Toronto (Canada). The company focuses on collaborations and partnerships with other pharmaceutical companies for the development of its pipeline products. In FY2022, Recordati incurred R&D expenses of EUR220.1 million, which as a percentage of total revenue, stood at 11.9%.